A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme.
Amyloid diseases are characterized by an aberrant assembly of a specific protein or protein fragment into fibrils and plaques that are deposited in various organs and tissues, often with serious pathological consequences. Non-neuropathic systemic amyloidosis is associated with single point mutations...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2003
|
| _version_ | 1797069551542730752 |
|---|---|
| author | Dumoulin, M Last, A Desmyter, A Decanniere, K Canet, D Larsson, G Spencer, A Archer, D Sasse, J Muyldermans, S Wyns, L Redfield, C Matagne, A Robinson, C Dobson, C |
| author_facet | Dumoulin, M Last, A Desmyter, A Decanniere, K Canet, D Larsson, G Spencer, A Archer, D Sasse, J Muyldermans, S Wyns, L Redfield, C Matagne, A Robinson, C Dobson, C |
| author_sort | Dumoulin, M |
| collection | OXFORD |
| description | Amyloid diseases are characterized by an aberrant assembly of a specific protein or protein fragment into fibrils and plaques that are deposited in various organs and tissues, often with serious pathological consequences. Non-neuropathic systemic amyloidosis is associated with single point mutations in the gene coding for human lysozyme. Here we report that a single-domain fragment of a camelid antibody raised against wild-type human lysozyme inhibits the in vitro aggregation of its amyloidogenic variant, D67H. Our structural studies reveal that the epitope includes neither the site of mutation nor most residues in the region of the protein structure that is destabilized by the mutation. Instead, the binding of the antibody fragment achieves its effect by restoring the structural cooperativity characteristic of the wild-type protein. This appears to occur at least in part through the transmission of long-range conformational effects to the interface between the two structural domains of the protein. Thus, reducing the ability of an amyloidogenic protein to form partly unfolded species can be an effective method of preventing its aggregation, suggesting approaches to the rational design of therapeutic agents directed against protein deposition diseases. |
| first_indexed | 2024-03-06T22:26:08Z |
| format | Journal article |
| id | oxford-uuid:56b94006-8313-49d1-94e7-ea6cd4306e2a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:26:08Z |
| publishDate | 2003 |
| record_format | dspace |
| spelling | oxford-uuid:56b94006-8313-49d1-94e7-ea6cd4306e2a2022-03-26T16:52:11ZA camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:56b94006-8313-49d1-94e7-ea6cd4306e2aEnglishSymplectic Elements at Oxford2003Dumoulin, MLast, ADesmyter, ADecanniere, KCanet, DLarsson, GSpencer, AArcher, DSasse, JMuyldermans, SWyns, LRedfield, CMatagne, ARobinson, CDobson, CAmyloid diseases are characterized by an aberrant assembly of a specific protein or protein fragment into fibrils and plaques that are deposited in various organs and tissues, often with serious pathological consequences. Non-neuropathic systemic amyloidosis is associated with single point mutations in the gene coding for human lysozyme. Here we report that a single-domain fragment of a camelid antibody raised against wild-type human lysozyme inhibits the in vitro aggregation of its amyloidogenic variant, D67H. Our structural studies reveal that the epitope includes neither the site of mutation nor most residues in the region of the protein structure that is destabilized by the mutation. Instead, the binding of the antibody fragment achieves its effect by restoring the structural cooperativity characteristic of the wild-type protein. This appears to occur at least in part through the transmission of long-range conformational effects to the interface between the two structural domains of the protein. Thus, reducing the ability of an amyloidogenic protein to form partly unfolded species can be an effective method of preventing its aggregation, suggesting approaches to the rational design of therapeutic agents directed against protein deposition diseases. |
| spellingShingle | Dumoulin, M Last, A Desmyter, A Decanniere, K Canet, D Larsson, G Spencer, A Archer, D Sasse, J Muyldermans, S Wyns, L Redfield, C Matagne, A Robinson, C Dobson, C A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. |
| title | A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. |
| title_full | A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. |
| title_fullStr | A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. |
| title_full_unstemmed | A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. |
| title_short | A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. |
| title_sort | camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme |
| work_keys_str_mv | AT dumoulinm acamelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT lasta acamelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT desmytera acamelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT decannierek acamelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT canetd acamelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT larssong acamelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT spencera acamelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT archerd acamelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT sassej acamelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT muyldermanss acamelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT wynsl acamelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT redfieldc acamelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT matagnea acamelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT robinsonc acamelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT dobsonc acamelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT dumoulinm camelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT lasta camelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT desmytera camelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT decannierek camelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT canetd camelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT larssong camelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT spencera camelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT archerd camelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT sassej camelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT muyldermanss camelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT wynsl camelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT redfieldc camelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT matagnea camelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT robinsonc camelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme AT dobsonc camelidantibodyfragmentinhibitstheformationofamyloidfibrilsbyhumanlysozyme |